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Background. 'e safety and efficacy of percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG)
for stable left main coronary artery disease (LMCAD) remains controversial.Methods. Digital databases were searched to compare
the major adverse cardiovascular and cerebrovascular events (MACCE) and its components. A random effect model was used to
compute an unadjusted odds ratio (OR). Results. A total of 43 studies (37 observational and 6 RCTs) consisting of 29,187 patients
(PCI 13,709 and CABG 15,478) were identified.'e 30-day rate ofMACCE (OR, 0.56; 95%CI, 0.42–0.76;p � 0.0002) and all-cause
mortality (OR, 0.52; 95% CI, 0.30–0.91; p � 0.02) was significantly lower in the PCI group. 'ere was no significant difference in
the rate of myocardial infarction (MI) (p � 0.17) and revascularization (p � 0.12). At 5 years, CABG was favored due to a
significantly lower rate of MACCE (OR, 1.67; 95% CI, 1.18–2.36; p �<0.04), MI (OR, 1.67; 95% CI, 1.35–2.06; p �<0.00001), and
revascularization (OR, 2.80; 95% CI, 2.18–3.60; p �<0.00001), respectively. PCI was associated with a lower overall rate of a stroke,
while the risk of all-cause mortality was not significantly different between the two groups at 1- (p � 0.75), 5- (p � 0.72), and 10-
years (p � 0.20). The Kaplan–Meier curve reconstruction revealed substantial variations over time; the 5-year incidence of
MACCE was 38% with CABG, significantly lower than 45% with PCI (p �<0.00001). Conclusion. PCI might offer early safety
advantages, while CABG provides greater durability in terms of lower long-term risk of ischemic events. 'ere appears to be an
equivalent risk for all-cause mortality.
1. Introduction
'e American College of Cardiology (ACC) and European
Society of Cardiology (ESC) guidelines, updated in 2019,
recommend CABG in patients with stable LMCAD with
favorable coronary anatomy and low-predicted surgical
mortality (class IB). 'e recommendations for PCI vary
depending upon the anatomical complexity (low, interme-
diate, and high) of the unprotected LMCAD and patient
complexity [1]. 'ese guidelines were based on summated
evidence from six major clinical trials. 'e 3-year EXCEL
trial which found PCI to be noninferior to CABG was the
cornerstone of these recommendations [2].
Recently reported EXCEL’s 5-year results demonstrated
continued noninferiority of PCI to CABG through 5 years
for patients with left main CAD [3]. Of concern was the use
of a new definition of MI, reportedly favoring the PCI arm,
in contravention of the previous protocol, which used the
'ird Universal Definition (UD) of MI, developed collab-
oratively by the ESC and ACC. 'e European Association
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for Cardio-'oracic Surgery (EACTS) officially withdrew
their support for ESC guidelines that endorse the use of
coronary stents in many patients with LMCAD.
'is growing controversy and the fact that six previously
conducted clinical trials have also demonstrated conflicting
results regarding the management of LMCAD have
prompted this meta-analysis in an attempt to provide clarity
on this issue.
2. Methods
2.1. Search Strategy and Data Extraction. 'e MEDLINE
(PubMed and Ovid), Embase, Clinicaltrials.org, and
Cochrane databases were queried till April 15, 2020, to
identify relevant observational cohort studies (OCS) and
randomized controlled trials (RCTs) (Figure 1). Studies
comparing the safety and efficacy of PCI with CABG in
LMCAD stenosis were included. 'e primary endpoint
included MACCE. Secondary outcomes included compo-
nents of MACCE (all-cause death, revascularization, stroke,
and myocardial infarction (MI)). 'e detailed search
strategy and map are given in Supplementary (S.). Appendix
(available here).
2.2. Data and Quality Analysis. 'e statistical analysis was
performed using the Cochran–Mantel–Haenszel test on a
random effect model to calculate an unadjusted odds ratio
(OR). Relative risk (RR) assessment for the dichotomous
outcomes of RCTs was also performed.'e probability value
of p< 0.05 was considered statistically significant. 'e “test
for overall effect” was reported as the z value corroborating
the inference from the 95% confidence interval (CI). A
stratified analysis based on the type of study (OCS vs. RCTs),
angiographic SYNTAX (Synergy between Percutaneous
Coronary Intervention with Taxus and Cardiac Surgery)
score (<0–32 vs. >32), and different stent designs was also
performed. Reconstruction of patient level data was made
possible by extreme magnification and digitization of the
Kaplan–Meier curves from individual RCTs. 'e Higgins I-
squared (I2) statistical model was used to assess variations in
outcomes of the included studies. Publication bias was il-
lustrated graphically using a funnel plot and calculated
quantitatively using Egger’s Regression Equation (ERE). 'e
methodological quality assessment of the included RCTs was
performed using the Oxford scoring scale and the Cochrane
collaboration tool for the systematic review and meta-
analysis. 'e Newcastle–Ottawa Scale was used for the bias
assessment of OCS. All statistical analyses were performed
using the Digitize and the Cochrane Review Manager
(RevMan) version 5.3.
2.3. Quality of the Included Studies. 'e overall quality of the
included RCTs was high (Figure 2). Due to adequate ran-
domization and allocation concealment in most studies, the
risk of selection bias in RCTs was low. 'e risk of perfor-
mance and detection bias was reduced due to the appro-
priate blinding of participants and outcomes, respectively.
Similarly, reporting and attrition bias across all studies were
reduced due to an adequate description of the study results
and an “intention to treat model,” respectively. 'e Oxford
scale of bias assessment showed the Jadad score≥ 3 indi-
cating high quality of the included RCTs.'e detailed quality
assessments (Oxford and Newcastle–Ottawa Scale) are given
in S. Tables 1, 2.
3. Results
3.1. Search Results and Study Characteristics. 'e initial
search revealed 15,741 articles. After removal of irrelevant
and duplicate items, 269 articles were deemed relevant for
full-text review. Of these, 226 articles were excluded based
on our selection criteria. 43 articles (6 RCTs and 37 OCS)
were qualified for quantitative analysis ([3–8], S. Ref 1–48).
'e preferred reporting items for systematic reviews and
meta-analyses (PRISMA) flow diagram is shown in Figure 1.
A total of 29,187 patients, 13,709 in the PCI and 15,478 in
the CABG group, were included. 'e mean age of patients
undergoing PCI was 66 and for CABG was 65 years,
comprising 74% and 77% male patients, respectively. All
patients had documented myocardial ischemia with ≥50%
stenosis of the LMCAD. 'e PRECOMBAT and SYNTAX
trials used the 1st generation drug-eluting stents (DES), and
the EXCEL and NOBLE trials used the 2nd generation DES.
About 10% of the NOBLE population had 1st generation
sirolimus-eluting Cypher stenting. Baseline characteristics
of patients were comparable except for antiplatelet therapy
(more in PCI) (Figure 3). 'e median follow-up duration
PubMed 7444
Embase 5370
Ovid 2354
Cochrane 542
Clinicaltrials.org
17
References 14
Total 15,741
Duplicates
8352
Remaining 7389 Irrelevant 7120
Full-text review 269
Quantitative
analysis 43
Clinical trials 6
Review 89
Meta-analyses 37
Insufficient data 67
Other reasons 33
Observational studies 37
Figure 1: PRISMA flow diagram of the included studies.
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was 4 years. 'e detailed definitions of trials, outcomes,
components of MACCE, inclusion criteria of studies, and
the baseline characteristics of included patients are given in
S. Tables 3–7.
3.2. Pooled Analysis of Overall Studies. A comprehensive
pooled analysis of the 43 studies favored PCI at the short-
term (30 days) and CABG at long-term follow-up (1 and 5
years from randomization) (Figure 4).
'e 30-day rate ofMACCE (OR, 0.56; 95%CI, 0.42–0.76;
p � 0.0002) and all-cause mortality (OR, 0.52; 95% CI,
0.30–0.91; p � 0.02) was significantly lower in the PCI group,
while the odds of MI (OR, 0.81; 95% CI, 0.60–1.09,;p � 0.17),
revascularization (OR, 0.65, 95% CI, 0.38–1.11; p � 0.12),
and all-cause mortality (OR, 0.52; 95% CI, 0.30–0.91;
p � 0.02) were comparable between the two groups. At 1
year, CABG was favored due to lower rate of MACCE (OR,
1.45; 95% CI, 1.21–1.75; p �<0.0001), MI (OR, 1.33; 95% CI,
1.04–1.70; p � 0.02), and revascularization (OR, 3.01; 95%
CI, 2.40–3.79; p �<0.00001). CABG continued to show a
favorable trend of lower rate of MACE (OR, 1.67; 95% CI,
1.18–2.36; p �<0.04), MI (OR, 1.67; 95% CI, 1.35–2.06;
p �<0.00001), and revascularization (OR, 2.80; 95% CI,
2.18–3.60; p �<0.00001) at 5 years. 'e rate of stroke was
significantly lower in the PCI arm at 30 days (OR, 0.37; 95%
CI, 0.19–0.71; p � 0.03), 1 year (OR, 0.50; 95% CI, 0.37–0.67;
p �<0.00001), and 5 year (OR, 0.60; 95% CI, 0.39–0.92;
p � 0.02).
Only four studies reported extended data at the 10-year
follow-up. 'ere was no significant difference between the
two groups in terms of MACCE (OR, 0.90; 95% CI,
0.55–1.45; p � 0.66), MI (OR, 1.19; 95% CI, 0.72–1.97;
p � 0.51), revascularization (OR, 2.74; 95% CI, 0.72–10.45;
p � 0.14), and stroke (OR, 0.73; 95% CI, 0.36–1.49; p � 0.38).
'e odds of all-cause mortality remained identical at 1 year
(OR, 0.96; 95% CI, 0.76–1.22; p � 0.75), 5 year (OR, 0.96;
95% CI, 0.78–1.19; p � 0.72), and 10 year (OR, 0.85; 95% CI,
0.67–1.09; p � 0.20) (Table 1 and S. Figures 1–4). 'e het-
erogeneity among the outcomes of studies at 30 days to 10
years ranged from I2 � 0% to I� 92%.
3.3. Pooled Analysis of the RCTs. Six RCTs comprising 4700
patients (PCI 2349 and CABG 2351) closely mirrored the
pooled results at all time points, except that the 1-year rate of
MI and MACE and the 5-year rate of stroke were identical
between PCI and CABG. 'e heterogeneity among the
outcomes of the included studies for all endpoints at 30 days
and 1 year and for MACCE and revascularization after
randomization was minimal (I2 � 0%–25%). Detailed results
are given in S. Figures 5–7.
Kaplan–Meier analysis of four major RCTs (EXCEL,
NOBLE, PRECOMBAT, and SYNTAX) showed a significant
variation in the incidence of primary composite outcome
over time with a cumulative rate of 45.0% (989 events) with
PCI and 38.6% (849 events) with CABG at 5 years. As
evident by the curve, PCI exhibited a numeric advantage
over CABG in the first 30 days, while there was no significant
difference inMACCE at 1 year. A significant deviation in the
curves was observed in favor of CABG, from 1 to 5 years.
Risk estimation by a shared frailty model at 5 years showed a
significantly lower risk of MACCE in CABG (HR, 1.34; 95%
CI, 1.16–1.47; p �<0.00001) (Figure 5).
3.4. Pooled Analysis of the Observational Cohort Studies.
Pooled results from 37 OCS (24,487 patients: PCI 11360 and
CABG 13127) were in agreement with the combined out-
comes of all studies (RCTs +OCS) and with the findings of
RCTs with few exceptions. In contrast to RCTs, the odds of
MACCE at the 1-year follow-up were significantly lower in
patients undergoing CABG (p �<0.0001). Unlike RCTs,
CABG was superior due to significantly lower odds of MI at
1 year (p � 0.005) and 5 year (p �<0.00001). Contrary to the
overall results of all studies, the odds of all-cause mortality at
30 days were identical between the two groups (OR, 0.52;
95% CI, 0.23–1.18; p � 0.12). 'e relative odds of all other
endpoints in patients undergoing PCI vs. CABG were
similar to the corresponding pooled risk ratios in the RCTs at
all time points (S. Table 9, S. Figures 8–13).
3.5. Subgroup Sensitivity Analysis of the 5-Year RCTs Data.
A subgroup analysis based on the anatomical complexity of
LMCAD, MI definition, cardiovascular mortality, and stent-
generations favored CABG at 5 years. In contrast to pooled
results, a significantly lower risk of nonprocedural (spon-
taneous) MI was seen in patients undergoing CABG (RR,
Boudrlot 2011
Buszman (LE MANS) 2008
Makikallio (NOBLE) 2016
Park (PRECOMBAT) 2011
Serruys (SYNTAX) 2009
Stone (EXCEL) 2019
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Figure 2: 'e methodological quality assessment of the included
studies showing minimal risk of bias.
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2.23; 95% CI, 1.53–3.27; p �<0.0001). 'ese results were
obtained after exclusion of periprocedural MI population
(Figure 6).
'e 5-year MACCE rate in a subgroup of patients with
both first (RR, 1.23; 95% CI, 1.02–1.48; p � 0.03) and 2nd
generation DES (RR, 1.36; 95% CI, 1.17–1.58; p �<0.0001)
was significantly higher compared to patients who under-
went CABG (Figure 6). Interestingly, the 5-year incidence of
MACCE was significantly lower in the CABG arm across all
tertiles of the SYNTAX score. Both low SYNTAX score RR,
1.24; 95% CI, 1.01–1.52; p � 0.04, and high SYNTAX score
RR, 1.40; 95% CI, 1.14–1.73; p � 0.001 favored CABG
(Figure 6). 'ere was no significant intergroup difference in
the incidence of cardiovascular mortality (RR, 1.06; 95% CI,
0.80–1.41; p � 0.69) at 5 years.
3.6. Publication Bias. On visual assessment of the funnel
plots, no significant publication bias was detected for
MACCE and its individual components at 1 and 5 years
(ERE≈p � 0.45 to p � 0.56) (Figure 7). Our funnel plots
were symmetrical, indicating that the limited scatter was due
to sampling variation and not publication bias (S.
Figures 14–23).
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Figure 3: Baseline characteristics of patients undergoing PCI vs. CABG (y-axis percentages).
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Favors CABGFavors PCI
MACCE 30-day
MACCE 1-year
MACCE 5-year
MI 30-day
MI 1-year
MI 5-year
Revasccualrization 30-day
Revasccualrization 1-year
Revasccualrization 5-year
Stroke 30-day
Stroke 1-year
Stroke 5-year
Mortality 30-day
Mortality 1-year
Mortality 5-year
Figure 4: Forest plot of all the studies (RCTs +OCS) showing pooled estimates of outcomes between PCI vs. CABG across different follow-
ups.
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4. Discussion
Our meta-analysis demonstrated a substantial relation-
ship between time since randomization and effect of
intervention on the primary composite endpoint. At 30
days, PCI was found to have a lower incidence of MACCE
with comparable odds of MI and the need for revascu-
larization. Patients undergoing PCI had 63% lower odds
of stroke compared to CABG. 'ese observations can be
attributed to PCI being a minimally invasive procedure,
dual antiplatelet therapy (DAPT), and the use of con-
temporary drug-eluting stents (DES). At 1 year, the rate
of MACCE and MI was lower in patients undergoing
CABG, albeit there was a 50% lower risk of stroke with
PCI.
In contrast to the recently published EXCEL trial and all
previous meta-analyses, PCI was associated with an in-
creased risk of MACCE by 67%, at 5 years from the index
procedure. A prominent impact of repeat unplanned re-
vascularization and MI appear to drive this difference. In
addition, the relative difference in stroke rate with PCI,
which decreased from 63% to 40%, plausibly linked with the
termination of dual antiplatelet therapy may be a contrib-
uting factor. Surprisingly, at an extended follow-up of 10
years, the risk of MACCE or its individual endpoints was
identical. It can be speculated that the 10-year data were
underpowered to assess the actual difference in outcomes, or
the benefits of CABG were attenuated with progressive
degenerative changes of the graft. Despite the prior men-
tioned differences in individual clinical outcomes, the risk of
all-cause mortality remained identical in both groups, and
this equipoise appears regardless of trial follow-up duration.
'e management of unprotected LMCAD with revas-
cularization is the accepted standard of care with clear
survival benefits compared with medical management alone
[9]. However, the decision about optimal revascularization
strategy has been debated for years. 'e SYNTAX study
suggested that the extent of anatomical complexity, as
denoted by the SYNTAX score, should be taken into account
when deciding between PCI and CABG [6]. For patients
with a higher SYNTAX score (>32), the rate of MACCE was
higher with PCI, while the rate was identical with a lower
SYNTAX score (<32). A high rate of repeat revascularization
seen with PCI was offset by a significantly higher proportion
of stroke with CABG leading to a similar rate of MACCE
between the two groups [6]. 'e PRECOMBAT trial mir-
rored the overall findings of the SYNTAX trial, with the
exception that the SYNTAX score tertile did not impact the
composite endpoint regardless of intervention strategy [8].
Contrary to these findings, the NOBLE trial found inferior
outcomes in terms of primary composite endpoint with PCI
p < 0.0001
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Figure 5: Kaplan–Meier analysis showing results favoring CABG
for lower cumulative incidence of MACCE (RCTs).
Table 1: Pooled results of all 43 studies showing comparison of odds ratio with 95% CI for primary and secondary endpoints of PCI vs.
CABG for across all follow-up duration.
Event 30 days 1 year 5 years 10 years
MACCE 0.56 (0.42–0.76,
p � 0.0002)
1.45 (1.21–1.75,
p �<0.0001) 1.67 (1.18–2.36,p � 0.04) 0.68 (0.44–1.06, p � 0.09)
MI 0.81 (0.60–1.09,
p � 0.17)
1.33 (1.04–1.70,
p � 0.02)
1.67 (1.35–2.06,
p �<0.00001) 1.21 (0.67–2.18, p � 0.53)
Revascularization 0.65 (0.38–1.11,
p � 0.12)
3.01 (2.40–3.79,
p �<0.00001) 2.80 (2.18–3.60,p �<0.00001) 2.95 (0.22–39.28,p � 0.41� 0.41)
Stroke 0.37 (0.19–0.71,
p � 0.03)
0.50 (0.37–0.67,
p �<0.00001) 0.60 (0.39–0.92,p � 0.02) 0.68 (0.28–1.65, p � 0.39)
All-cause
mortality
0.52 (0.30–0.91,
p � 0.02)
0.96 (0.76–1.22,
p � 0.75)
0.96 (0.78–1.19,
p � 0.72) 0.79 (0.60–1.05, p � 0.10)
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Ahn (PRECOMBAT) 2015
Holm (NOBLE) 2020
Morice (SYNTAX) 2014
Stone (EXCEL) 2019
Total (95% CI)
Total events
38
150
68
140
396 308
231
538
221
686
1676 1643 100.0
25
96
60
127
201
536
196
710
13.8
30.3
24.6
31.3
1.32 [0.83, 2.11]
1.56 [1.24, 1.95]
1.01 [0.75, 1.34]
1.14 [0.92, 1.42]
1.24 [1.01, 1.52]
Heterogeneity: tau2 = 0.02; chi2 = 6.54, df = 3 (P = 0.09); I2 = 54%
Test for overall effect: Z = 2.05 (P < 0.04)
Study or subgroup Risk ratio
M-H, random, 95% CI
Risk ratio
M-H, random, 95% CI
CABG
TotalEvents
PCI
TotalEvents
Weight
(%)
0.01 0.1 1 10 100
Favours PCI Favours CABG
(a)
Total events
Ahn (PRECOMBAT) 2015
Holm (NOBLE) 2020
Morice (SYNTAX) 2014
Stone (EXCEL) 2019
Total (95% CI)
14
15
62
56
147 112
58
46
135
228
467 489 100.0
13
14
43
42
68
56
149
216
9.7
11.4
44.5
34.4
1.30 [0.71, 2.41]
1.59 [1.17, 2.17]
1.26 [0.89, 1.80]
1.26 [0.65, 2.46]
1.40 [1.14, 1.73]
Heterogeneity: tau2 = 0.00; chi2 = 1.12, df = 3 (P = 0.77); I2 = 0%
Test for overall effect: Z = 3.21 (P = 0.001)
Study or subgroup Risk ratio
M-H, random, 95% CI
Risk ratio
M-H, random, 95% CI
CABG
TotalEvents
PCI
TotalEvents
Weight
(%)
0.01 0.1 1 10 100
Favours PCI Favours CABG
(b)
Holm (NOBLE) 2020
Ahn (PRECOMBAT) 2015
1.3.4.1 First Gen DES
1.3.4.2 Second Gen DES
Morice (SYNTAX) 2014
Stone (EXCEL) 2019
7.43004230052
22.9348103357
657 648 30.3
145182
130
1.24 [0.85, 1.80]
1.23 [1.00, 1.52]
1.23 [1.02, 1.48]
22.8592110592165
46.9957228948
1540 1549 69.7
338455
290
1.50 [1.21, 1.86]
1.28 [1.11, 1.49]
1.36 [1.17, 1.58]
100.021972197
637 483
1.31 [1.19, 1.45]
Total events
Subtotal (95% CI)
Heterogeneity: tau2 = 0.00; chi2 = 0.00, df = 1 (P = 0.98); I2 = 0%
Test for overall effect: Z = 2.22 (P = 0.03)
Total events
Subtotal (95% CI)
Heterogeneity: tau2 = 0.00; chi2 = 1.38, df = 1 (P = 0.24); I2 = 28%
Test for overall effect: Z = 4.09 (P < 0.0001)
Total events
Total (95% CI)
Heterogeneity: tau2 = 0.00; chi2 = 2.05, df = 3 (P = 0.56); I2 = 0%
Test for subgroup differences chi2 = 0.68, df = 1 (P = 0.41) I2 = 0%
Test for overall effect: Z = 5.27 (P < 0.00001)
Study or subgroup Risk ratio
M-H, random, 95% CI
Risk ratio
M-H, random, 95% CI
CABG
TotalEvents
PCI
TotalEvents
Weight
(%)
0.01 0.1 1 10 100
Favours PCI Favours CABG
(c)
Total events
Ahn (PRECOMBAT) 2015
Holm (NOBLE) 2020
Morice (SYNTAX) 2014
Stone (EXCEL) 2019
Total (95% CI)
11
25
30
106
172 157
300
592
357
948
2197 2197 100.0
20
25
23
89
300
592
348
957
13.0
20.2
21.3
45.4
0.55 [0.27, 1.13]
1.00 [0.58, 1.72]
1.27 [0.75, 2.14]
1.20 [0.92, 1.57]
1.06 [0.80, 1.41]
Heterogeneity: tau2 = 0.03; chi2 = 4.42, df = 3 (P = 0.22); I2 = 32%
Test for overall effect: Z = 0.39 (P = 0.69)
Study or subgroup Risk ratio
M-H, random, 95% CI
Risk ratio
M-H, random, 95% CI
CABG
TotalEvents
PCI
TotalEvents
Weight
(%)
0.01 0.1 1 10 100
Favours PCI Favours CABG
(d)
Figure 6: Continued.
6 Journal of Interventional Cardiology
compared to CABG irrespective of coronary lesion com-
plexity [4].
'e recently reported EXCEL trial added further un-
certainty to this already confusing issue [3]. 'e arising
controversy about the identical rates of the primary com-
posite endpoint between PCI and CABG patients focus
primarily on the following: (1) revascularizations were not
considered as part of the reported MACCE, potentially
tilting the results in favor of PCI over CABG, as evidenced by
a higher MACCE in PCI (31.3% vs. 24.9%) once revascu-
larization was taken into account. (2) Although the rate of
nonprocedural MI with PCI were twice that in the CABG
(6.8% vs. 3.5%), the identical odds of overall MI and un-
adjusted MACCE were driven by lower rate of periproce-
dural MIs in the PCI arm (3.9% vs. 6.1%). (3) MI diagnosis
was based on CK-MB over high sensitive cardiac troponin,
potentially underestimating the rate of periprocedural MI in
PCI-treated patients.
On review, we found 38 prior meta-analyses, suggesting
that PCI and CABG have an equivalent risk of MACCE (S.
Ref 49–86, S. Table 10). However, in light of recent evidence,
the applicability of their results is limited. Most of these
studies were published before the completion of 5-year
EXCEL, 5-year NOBLE, 10-year SYNTAX, and 10-year
PRECOMBAT trials [3, 4, 10, 11]. All previous meta-ana-
lyses reported a crude MACCE and MI rate, unadjusted for
the rate of revascularization and unstratified for peri-
procedural MI, respectively. 'e follow-up duration was
short, and observational data and methodological quality
were mostly missing. 'e most recent meta-analysis in-
cluded only 5 studies, and the composite endpoint
(MACCE), a commonly accepted yardstick of efficacy, was
neglected [12]. Together, these limitations underestimated
the long-term beneficial effects of CABG and overstated the
benefits of PCI.
'e present meta-analysis represents the most com-
prehensive study seeking to address the limitations of
previous studies and assist in the clinical decision making
for the management of LMCAD. Unlike previous meta-
analyses, we collated findings of 43 studies, including the
more contemporary clinical trials. We have demonstrated
a significantly higher rate of MACCE with PCI at 5 years,
irrespective of the SYNTAX score tertiles and DES
generation. 'ese findings contrast with the recent EX-
CEL study and all previous meta-analyses, which have
tended to show an identical rate of MACCE between PCI
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Figure 6: Forest plots showing an individual and pooled RR for RCTs comparing the MACCE in PCI vs. CABG for LMCAD at 5 years ((a)
low SYNTAX, (b) high SYNTAX, (c) DES, (d) cardiovascular mortality, and (e) nonprocedural MI). 'e pooled RRs with 95% CI were
calculated using random-effects models. Weight refers to the contribution of each study to the overall pooled estimate of the treatment
effect. Each square and horizontal line denotes the point estimate and 95% CI for each trial’s RR, respectively. 'e diamonds signify the
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2
1.5
1
0.5
0
SE
 (l
og
 [O
R]
)
0.1 1 10 1000.01
OR
(a)
0.5
0.4
0.3
0.2
0.1
0
SE
 (l
og
 [O
R]
)
0.1 1 10 1000.01
OR
(b)
Figure 7: Funnel plot showing minimal publication bias across studies comparing the pooled estimate of MACCE at 1- and 5-year follow up.
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and CABG, persisting at long follow-up durations (1–5
years).
4.1. Limitations. Our study is constrained by the limitations
of the included studies. Patient level data were missing to
determine the impact of PCI techniques or account for the
differential use of antiplatelet agents. CABG-related com-
plications such as bleeding, renal failure, and postprocedure
infections were not assessed. 'e cumulative incidence of
outcomes at 10 years was underpowered. Moreover, due to
the differential risk of need for revascularization after the
index procedure (PCI vs. CABG) and unmeasured con-
founding factors, individual patient level data such as patient
age, life expectancy, operators skills, aortic calcifications,
patient comorbidities, and bleeding risks should be con-
sidered as a cornerstone during the decision making process
for LMCAD intervention.
5. Conclusion
In patients with LMCAD, PCI might offer early safety ad-
vantages, while CABG seems to provide greater durability in
terms of consistently lower risk of MACCE and reduced
need for revascularization.'ere appears to be an equivalent
risk for all-cause mortality between both procedures.
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